Dear Core User,

Due to the current situation with COVID-19, per directives from Senior management at Mass General Brigham and the Hospitals, this research core facilities will have a hiatus in their service offering. We will not be offering service till we are advised to resume operation.

Please stay safe in this challenging time and we look forward to working with you in the future.

Viral Vector Core

The MGH Vector Core Facility was founded in 2008 with the goal to meet the increasing need of scientists in academia and industry for recombinant viral vectors capable of achieving efficient and long-lasting genetic modification of cells and model organisms. Since that time we have become an increasingly valuable partner in biomedical research, as researchers and companies from across the US continue to solicit our services in the fight against rare and inherited diseases. Our viruses have been featured in a number of publications and as therapeutic agent of investigation in clinical trials.

We aim to provide three main services to our clients:

  1. We prepare high-titer, high-quality research-grade lentivirus, retrovirus, and adeno-associated (AAV) vector stocks at competitive prices in a timely manner.
  2. We work with investigators and companies to design vectors for tailored for their specific applications.
  3. We provide scientific consultation to identify the best strategies to achieve project goals in a cost-sensitive and timely manner.
  4. Are you in need of other vector types not currently offered by our core? contact us and we will make every effort to answer your need. 

We look forward to discussing the ways in which we can help you achieve success in your research. Please contact us for more information.

Please inform the Core of any papers you publish using a virus derived from the Core.